Product Description

Chanazone 1 g is indicated for use in non-food producing horses to manage pain and inflammation associated with a range of musculoskeletal and soft tissue conditions. The apple-flavoured powder may be mixed with a quantity of bran or oats for ease of administration. It is advisable not to administer hay immediately before or during dosing, as this may delay the absorption of phenylbutazone and the onset of a clinical effect.

For Horses:

Treatment of musculoskeletal conditions requiring pain relief and reduction of inflammation — including lameness associated with osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation, particularly where continued mobility is considered desirable

Limiting post-surgical inflammation, myositis and other soft tissue inflammation

Use as an anti-pyretic where clinically indicated, for example in viral respiratory infections

Which Animals Can Use Chanazone 1 g, Oral Powder?

Chanazone 1 g is licensed for use in non-food producing horses only. It must not be used in horses intended for human consumption. Treated horses may never be slaughtered for human consumption, and the horse must have been declared as not intended for human consumption under national horse passport legislation. Always use only under the direction of your vet, who will confirm passport status and suitability before prescribing.

Available Strengths & Sizes

Please order the exact strength and pack size as specified on your veterinary prescription.

Note: Each 5 g sachet contains 1 g of phenylbutazone (200 mg/g). Individual single sachets may also be available.

Directions for Use

This is a prescription medication and must be used exactly as directed by your veterinary surgeon. Dosage is adjusted according to the horse's body weight and individual clinical response, typically starting at a higher loading rate then stepping down to a maintenance level. Refer to the dispensing label and product datasheet for full dosing instructions. Do not exceed the stated dose or duration of treatment, and discontinue if no response is evident after four to five days.

Contraindications

Source: SPC Section 4.3 / Datasheet Contra-indications

Do not use in animals with known hypersensitivity to the active substance phenylbutazone or to any of the excipients (glucose monohydrate, povidone, apple flavour, xanthan gum, crospovidone)

Do not use in animals suffering from cardiac (heart) disease

Do not use in animals suffering from hepatic (liver) disease

Do not use in animals suffering from renal (kidney) disease

Do not use where there is a possibility of gastrointestinal ulceration or bleeding

Do not use where there is evidence of a blood dyscrasia (blood cell disorder)

Do not use in animals suffering from thyroid disease

Do not use in animals with severe hypertonia

Do not use in animals with lesions of the intestinal mucosa caused by parasitic infestations

Do not administer concurrently with other NSAIDs or within 24 hours of another NSAID

Storage & Handling

This veterinary medicinal product does not require any special storage conditions. Keep out of reach of children and animals at all times. Do not mix with any other veterinary medicinal product. Dispose of any unused product or waste materials in accordance with local requirements — do not dispose of via wastewater.

Withdrawal periods:

Not for use in horses intended for human consumption

Treated horses may never be slaughtered for human consumption; the horse must have been declared as not intended for human consumption under national horse passport legislation — this is an irreversible decision

Important Warnings

Source: SPC Sections 4.4 & 4.5 / Datasheet Contra-indications & Warnings

Animal precautions:

Do not exceed the stated dose of 8.8 mg/kg/day — the therapeutic index of phenylbutazone is low

The clinical effects of phenylbutazone can persist for at least three days after cessation of therapy; this should be borne in mind when examining horses for soundness

Use in animals under 6 weeks of age or in aged animals may involve additional risk; if such use cannot be avoided, careful clinical management is required

Avoid use in any dehydrated, hypovolaemic or hypotensive horse as there is a potential risk of increased renal toxicity; ensure water is readily available throughout the treatment period

NSAIDs can inhibit phagocytosis; in inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be initiated

Ponies are particularly sensitive to gastric ulceration with this product, even at therapeutic doses; diarrhoea, oral ulceration and hypoproteinaemia may also occur in ponies

Overdosing may result in gastric and large intestinal ulceration, general enteropathy, renal papillary damage and subcutaneous oedema (especially under the jaw) due to plasma protein loss; in case of overdose, CNS effects including excitement and seizures, haematuria and acidosis have also been reported; there is no specific antidote — treat symptomatically

FEI regards phenylbutazone as a prohibited substance; administration should be in accordance with FEI recommendations if relevant

Use in pregnancy: foetotoxic effects have been recorded in experimental species at high doses; use in pregnant mares only after benefit/risk assessment by the responsible veterinarian; avoid use around the time of parturition

Use in lactation: use only after benefit/risk assessment by the responsible veterinarian

Human safety warnings:

This product may cause hypersensitivity (allergic) reactions in persons sensitised to phenylbutazone — either via skin contact or accidental inhalation

People with known hypersensitivity to phenylbutazone or any of the excipients must avoid contact with this product

If symptoms such as skin rash develop following exposure, seek medical advice and show the physician this warning; swelling of the face, lips or eyes, or difficulty breathing, are serious symptoms requiring urgent medical attention

The product can be irritating to the skin and eyes; avoid eye contact; in the event of accidental eye contact, irrigate immediately with plenty of clean water; if irritation persists, seek medical advice

Avoid ingesting the powder; in the event of accidental ingestion, seek medical advice immediately and show the product packaging to the physician

Wash any exposed skin and hands thoroughly after use

Drug interactions:

Do not administer concurrently with other NSAIDs or within 24 hours of another NSAID

Concurrent administration of potentially nephrotoxic drugs should be avoided; there is a particular risk of increased renal toxicity with concurrent aminoglycoside antibiotics

Concomitant use of glucocorticoids, other NSAIDs or anticoagulants increases the risk of adverse effects

Therapeutic efficacy of diuretics may be reduced when used in combination with phenylbutazone

Phenylbutazone is extensively bound to plasma proteins and may displace or be displaced by other highly protein-bound drugs including sulphonamides and warfarin, with a potential for increased pharmacologically active concentrations and toxicity

Phenylbutazone may interfere with the metabolism of warfarin and barbiturates; concurrent therapy with other therapeutic agents should be undertaken with caution

The pharmacokinetics of penicillin and gentamicin products may be affected by concurrent phenylbutazone, with a possible reduction in therapeutic efficacy

Phenylbutazone induces hepatic microsomal enzyme activity

POM-V Prescription Notice

This product is a Prescription Only Medicine — Veterinary (POM-V). It may only be supplied by a veterinary surgeon or, when prescribed by a veterinary surgeon, by a pharmacist or SQP. A valid veterinary prescription is required before this product can be dispensed.

MA Number: Please refer to product packaging (Decentralised Procedure reference: UK/V/0571/001/DC — MA holder: Chanelle Pharmaceuticals Manufacturing Ltd. Confirm Vm number via VMD Product Information Database.)